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CLINICAL AND EPIDEMIOLOGIC RESEARCH
The Spectrum of Eye Disease in Hospitalized Adults
Living with HIV, 1995–2010
Christopher Miller, MD,1 William R. Short, MD, MPH,1,6 Lorena Perez-Povis, MD,1,2 Josephine Lontok, MD,1
Christopher Fecarotta, MD,3 Mengdan Liu,4 Jocelyn Sendecki,5 and Katherine Belden, MD1,6
Abstract
Eye disease is a well-documented complication of HIV infection. Opportunistic infections generally comprised
the majority of pre-antiretroviral therapy (ART) eye complications. With the introduction of ART, opportunistic
infections diminished. However, early ART regimens were cumbersome regarding side effects and pill burden,
making patient compliance difficult. Newer ART regimens are better tolerated and consist of fewer pills, the-
oretically making compliance easier and therapy more effective. The aim of this chart review study is to examine
eye disease epidemiology in HIV patients as ART has evolved. We reviewed 222 admissions at Thomas Jefferson
University Hospitals for 188 patients. These cases were divided into two groups. The first group was comprised
of patients admitted from 1995 through 2003, while the second group consisted of patients admitted from 2003 to
2010. Eye disease epidemiology was compared between the two groups. Our study did note a significant
decrease in eye diseases caused by opportunistic infections in the 2003–2010 patient group. Noninfectious eye
disease is a significant complication in this group.
Introduction
In the pre-highly active antiretroviral therapy era(HAART, or ART; please note that HAART serves as a
historical term for this article. We will refer to such HIV
treatment regimens as ‘‘antiretroviral therapy’’ or ART),
opportunistic infections of the eye were frequent and often
severe.1 However, the epidemiology of eye involvement in
HIV has changed as a result of our ability to control HIV
disease with newer ART regimens.2–7 The incidence and
overall severity of opportunistic infectious diseases of the
eye have decreased, along with other sequelae of immuno-
suppression.
The stark contrast in HIV eye diseases before and after
the introduction of ART has been described in the litera-
ture.8 However, epidemiologic differences in HIV eye dis-
ease that have occurred during the ART era have not been
as well established. Recent studies still estimate that ap-
proximately 40% of patients with AIDS and no evidence of
infectious retinitis still demonstrate significant visual im-
pairment.9 Such ongoing disease may be indirectly due to a
persistent systemic inflammatory state (the hypothesized
etiology of HIV retinopathy) or due to the aforementioned
increase in incidence of additional non-AIDS related co-
morbidities in today’s HIV patients (diabetes or hyperten-
sion, for instance).
The aim of this study is to review retrospectively a popu-
lation of HIV-positive hospitalized patients with eye disease
over this time period of ART evolution. We then compare the
epidemiology of eye disease in patients seen in the early era of
ART with the more recent era of ART.
Methods
Patient population
HIV-infected adults with active ocular disease admitted as
inpatients for any reason to the Wills Eye Institute and Tho-
mas Jefferson University Hospitals between December 30,
1995 and October 31, 2010 were identified through a search of
applied International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9) codes including HIV (042,
V08) and any ocular diagnosis (360–379).
An initial 422 admissions were identified. Of these, 9 charts
were unavailable, 129 admissions were noted to have no ac-
tive ocular diagnosis, 59 were noted to be duplicate patient
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admissions without a new ocular diagnosis, and 3 admissions
did not have confirmed HIV by history or laboratory testing.
These cases were excluded, leaving 222 admissions amongst
188 patients.
A retrospective chart review was conducted. Data for the
study were collected from included charts. Demographic pa-
tient information collected included age, gender, race, sub-
stance abuse history, CD4+ T cells/lL, HIV viral load, current
antiretroviral therapy, and select co-morbidities (Table 1).
Outcome
Active ocular diagnoses were recorded for each admission.
Visual acuity was documented when available (160 of 188
patients had a full ophthalmologic exam with full visual
acuity). All patients in the study with documented visual
acuity received a full ophthalmologic exam. For the 22 patients
without documented visual acuity, documentation of further
ophthalmologic examination was not recorded.
Patients and their active ocular diagnoses were divided
into comparison groups based on date of presentation. An
‘‘Early ART’’ arm of the study consisted of presentations from
December 30, 1995 through June 30, 2003. A ‘‘Late ART’’ arm
of the study consisted of presentations from July 1, 2003
through October 31, 2010.
For this study, 2003 was chosen as a separation time point
between study groups. Prior to 2003, protease inhibitor (PI)
regimens still proved cumbersome and triple-nucleotide re-
verse transcriptase inhibitor (NRTI) regimens still remained in
use. In 2003 and beyond, newer, better-tolerated medications
such as atazanavir, fosamprenavir, and fixed-dose combi-
nation pills such as tenofovir/emtricitabine and tenofovir/
emtricitabine/efavirenz became available. Therefore, 2003
seemed a reasonable time to demarcate an ‘‘early’’ time frame
capturing patients on first-generation PIs and NRTIs versus a
‘‘late’’ time frame capturing patients on modern PIs, fixed-
dose combination pills, and NNRTIs.
Statistics
p Values were obtained with the unpaired t-test, chi-square
test, or Fisher’s exact test and adjusted by false discovery rate
methods, when indicated.
Results
From the 222 admissions, 252 active ocular diagnoses were
identified (please refer to Table 4 for a complete breakdown
by anatomic location). Sixty patients were included in the
early ART arm of the study, and 128 patients were included in
the late ART arm (Table 1).
Immunologic and virologic comparison of the two patient
groups illustrated a significantly higher median CD4 + count
in the late ART patients comparedwith the early ART patients
(108 vs. 40 cells/lL). The late ART group also had signif-
icantly fewer patients with uncontrolled viral load (defined
as > 400 copies/mL) compared with the early ART group
(65% vs. 88.5% of patients). In addition, late ART patients
were less likely to have had an opportunistic infection in the
past (36.4% of late ART patients had a history vs. 72.2% of
early ART patients).
Table 1. Demographicsa
Demographics All patients (n = 188) Early ART (n = 60) Late ART (n = 128) p Value
Age (yrs) (median) 50 51 50 0.2491
Gender (% male) 68.6 73.3 66.4 0.34
Race (%) 0.032
White non-hispanic 26 15 31.2
Black non-hispanic 68.6 81.7 62.4
Other 5.4 3.3 6.4
Substance abuse (%) 32.8, n= 183 31.6, n= 57 33.3, n = 126 0.8149
Tobacco abuse (%) 29, n = 183 26.3, n= 57 30.2, n = 126 0.5956
HIV history
Median time (yrs) since HIV diagnosis 6, n = 85 6, n= 39 7.5, n = 46 0.0673
Median CD4+ T-cells (cells/lL) 83, n = 143 40, n = 50 108, n = 93 < 0.0001
% CD4+ T-cells < 200 cells/lL 72, n = 143 88, n = 50 63.4, n = 93 0.0052
% Patients with HIV viral load > 400 copies/mL 72.1, n = 86 88.5, n= 26 65, n= 60 0.0259
Current antiretroviral therapy (%) 58.5 51.7 61.7 0.1922
History of opportunistic infection 47.4, n= 175 72.2, n= 54 36.4, n = 121 < 0.0001
Selected co-morbidities (%) N = 183 N = 57 N = 126
Diabetes mellitus 13.7 7 16.7 0.0784
Malignancy 11.5 1.8 15.9 0.0055
Cardiovascular disease 20.8 15.8 23 0.2644
Chronic kidney disease 8.2 8.8 7.9 1
Chronic viral hepatitis 20.8 17.5 22.2 0.47
aNot all demographic information for each patient was available.
Table 2. Infectious vs. Noninfectious
Ocular Diagnoses
Total
diagnoses (%)
N= 252
Early
ART (%)
N= 77
Late
ART (%)
N= 175 p Value
Infectious
diagnosis
43 54.6 37.7 0.0129
Noninfectious
diagnosis
57 45.5 62.3
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The late ART group of patients, however, tended to have
more co-morbidities compared to the early ART patients.
Most significantly, patients in the late ART group had a 15.9%
prevalence of malignancy versus only a 1.8% incidence in the
early ART group. Late ART patients also had a significantly
higher prevalence of diabetes mellitus compared to their early
ART counterparts (16.7% vs. 7% prevalence). While not sta-
tistically significant, late ART patients also tended to have a
higher prevalence of cardiovascular disease and chronic viral
hepatitis (Table 1).
Among the early ART patients, 77 ocular diseases were
diagnosed, while 175 ocular diseases were diagnosed in
the late ART group. Ocular disease in both groups combined
was predominately noninfectious (57%). Ocular diagnoses
were compared in early and late ART groupings. Early ART
diagnoses had significantly more infectious eye disease oc-
currence compared to the late ART group (54.6% of cases vs.
37.7%) (Table 2).
Themost frequent ocular diagnoses (from Table 4) found in
the early and late ART groups were compared with p values
calculated for the differences in prevalence (Table 3) (note that
p values were not calculated for differences in all diagnoses
from Table 4, just for themost frequent that appear in Table 3).
Most notably, 28.6% of ocular disease in the early ART group
was CMV retinitis (Fig. 1) compared to only 7.4% in the late
ART group. This diagnosis represented the highest burden of
ocular disease in early ART patients by a large margin. In
contrast, the incidence of ocular disease diagnoses in the late
ART group was more evenly distributed amongst a wide
range of categories.
The late ART group did have a significantly higher rate of
severe vision impairment, however, when visual acuity was
documented. Forty-eight patients in the early ART group and
112 patients in the late ART group had visual acuity docu-
mented. While the percentage of patients with ‘‘mild’’ visual
impairment ( < 20/40 but ‡ 20/200) was roughly equal (22.9%
of early ART patients vs. 19.6% of late ART patients,
p value of 0.64), the percentage of patients with ‘‘severe’’ vi-
sual impairment (< 20/200)was significantlymore for the late
ART group (37.5% of early ART patients versus 58% of late
ART patients, p value of 0.02).
Discussion
Ocular disease is associated with human immunodefi-
ciency virus (HIV) infection.10–12 Ocular manifestations
of HIV infection have been well described in the pre-ART era
of HIV infection when patients frequently developed se-
vere immunodeficiency followed by the development of
opportunistic infections. Direct therapy (ganciclovir for cy-
tomegalovirus, or CMV retinitis, for instance) for such op-
portunistic infections provided limited benefit in patients
suffering from a progressively failing immune system.13
With the approval of zidovudine as the first antiretroviral
therapy for HIV in 1987, the face of HIV disease began to
change. The most dramatic change came in the mid-1990s
with the introduction of ART, which made preservation of
T-cell immunity and suppression of HIV possible. Early ART
regimens, however, were inconvenient and cumbersome for
patients due to high pill burdens, food restrictions, and in-
tolerable side effects.2–7 Drug compliance, and therefore
control of HIV disease, remained a challenge. With time,
however, drugs with better tolerability, potency, and efficacy
have been developed. Such developments have even made it
possible to include a complete ART regimen co-formulated
into one pill taken once daily. As a result, compliance and
control of HIV are now much more realistic goals.
Eye disease caused by infectious agents such as Toxoplasma
gondii (Fig. 5), varicella-zoster virus (VZV) (Fig. 3), and, most
notably, CMV (Fig. 1), were disproportionately represented in
HIV patients before HAART became widely available. One
autopsy study from the pre-ART era found a 32% incidence of
postmortem HIV-infected patients with evidence of CMV
retinitis,14 and that the incidence of clinically apparent CMV
retinitis in individuals with severe T-cell impairment (CD4 +
< 100 cells/lL) may be as high as 25%.15 Frequently, HIV-
infected patients with CMV retinitis progressed to retinal
detachment and severe visual impairment months after the
onset of visual disturbance.
As control of HIV has improved, the incidence of opportu-
nistic infections decreased.2–7,11 One epidemiologic study from
1996 to 2004 found a 92% decrease in AIDS-related mortality in
HIV patients while ART utilization increased from 43% to 82%
Table 3. Most Frequent Ocular Diagnoses By Early and Late ART Groups
Total diagnoses (%) Early ART (%) Late ART (%)
Diagnosis N = 252 N= 77 N= 175 p Value
Noninfectious retinopathy 13.9 18.2 12 0.4097
CMV retinitis (Fig. 1) 13.9 28.6 7.4 < 0.0001
Retinal detachment (Fig. 4) 7.6 6.5 8 1
Ulcerative keratitis 7.1 3.9 8.6 0.4097
Necrotizing herpetic retinitis/viral retinitis (Fig. 2) 5.6 5.2 6.3 1
Preseptal cellulitis 3.6 3.9 3.4 1
Trauma 3.2 0 4.6 0.4097
Cataract 2.8 0 4 0.4097
Ocular syphilis 2.8 2.6 2.9 1
Cranial nerve palsy 2.8 0 4 0.4097
Conjunctivitis 2.4 2.6 2.3 1
Conjunctival hemorrhage 2.4 0 3.4 0.4097
Glaucoma 2.4 1.3 2.9 1
Noninfectious uveitis 2.4 3.9 1.7 0.7003
Endogenous endophthalmitis 1.9 1.3 2.3 1
Optic neuritis 1.9 3.9 1.1 0.4097
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Table 4. Active Ocular Diagnoses by Anatomic Location
Eye anatomic location All diagnoses (n = 252) Early ART (n = 77) Late ART (n = 175)
Adnexa/orbit 44 (17.4%) 10 34
Eyelids 15 (5.9%) 5 10
Preseptal cellulitis 9 (3.6%) 3 6
Blepharitis (infectious) 3 (1.2%) 2 1
Ectropion 2 (0.8%) 0 2
Entropion 1 (0.4%) 0 1
Orbit and surrounding tissues 11 (4.4%) 1 10
Ocular invasive tumor 4 (1.6%) 0 4
Orbital cellulitis 3 (1.2%) 1 2
Thyroid ophthalmopathy/exophthalmos 2 (0.8%) 0 2
Infected eye implant 1 (0.4%) 0 1
Non-infectious frozen globe 1 (0.4%) 0 1
Eyelid/orbit 8 (3.2%) 0 8
Trauma 8 (3.2%) 0 8
Lacrimal ducts 6 (2.4%) 4 2
Dry eye syndrome 4 (1.6%) 4 0
Dacryostenosis 1 (0.4%) 0 1
Dacryostenosis (infectious) 1 (0.4%) 0 1
Combined 4 (1.6%) 0 4
Herpes zoster ophthalmicus 4 (1.6%) 0 4
Anterior segment disease 59 (23.4%) 11 48
Cornea 24 (9.5%) 5 19
Ulcerative keratitis 18 (7.1%) 3 15
Noninfectious 7 (2.8%) 2 5
Infectious 11 (4.4%) 1 10
Non-ulcerative keratitis 3 (1.2%) 2 1
Corneal scar 2 (0.8%) 0 2
Superficial punctate keratopathy 1 (0.4%) 0 1
Lenses 13 (5.2%) 2 11
Cataract 7 (2.8%) 0 7
Presbyopia 4 (1.6%) 2 2
Posterior synechiae 1 (0.4%) 0 1
Lens dislocation 1 (0.4%) 0 1
Conjunctiva 12 (4.8%) 2 10
Acute conjunctivitis 6 (2.4%) 2 4
Conjunctival hemorrhage 6 (2.4%) 0 6
Anterior chamber 7 (2.8%) 1 6
Glaucoma 6 (2.4%) 1 5
Hyphema 1 (0.4%) 0 1
Pupil 2 (0.8%) 0 2
Pupillary margin degeneration 1 (0.4%) 0 1
Anisocoria 1 (0.4%) 0 1
Sclera 1 (0.4%) 1 0
Episclertitis (infectious) 1 (0.4%) 1 0
Posterior segment disease 112 (44.4%) 45 67
Retina 107 (42.5%) 45 62
CMV retinitis 35 (13.9%) 22 13
Noninfectious retinopathy 35 (13.9%) 14 21
HIV retinopathy (Fig. 2) 23 (9.1%) 11 12
DM retinopathy 9 (3.6%) 2 7
Retinal hemorrhage 1 (0.4%) 0 1
HTN retinopathy 1 (0.4%) 1 0
Sickle cell retinopathy 1 (0.4%) 0 1
Retinal detachment 19 (7.6%) 5 14
Retinal detachment 16 (6.3%) 4 12
Proliferative vitreoretinopathy 2 (0.8%) 0 2
Retinal tear 1 (0.4%) 1 0
Necrotizing herpetic retinitis/viral retinitis 15 (5.6%) 4 11
Cryptococcal retinitis 1 (0.4%) 0 1
Lattice degeneration 1 (0.4%) 0 1
Macular hole 1 (0.4%) 0 1
Vitreous 1 (0.4%) 0 1
Vitreous syneresis 1 (0.4%) 0 1
(continued)
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Table 4. (Continued)
Eye anatomic location All diagnoses (n= 252) Early ART (n= 77) Late ART (n = 175)
Choroid 2 (0.8%) 0 2
Choroidal hemorrhage 1 (0.4%) 0 1
Choroidal detachment 1 (0.4%) 0 1
Retina vessels 2 (0.8%) 0 2
Retinal vein occlusion 2 (0.8%) 0 2
Anterior/posterior segment disease 18 (7.1%) 6 12
Ocular syphilis 7 (2.8%) 2 5
Panuveitis 5 (1.9%) 2 3
Retinitis 2 (0.8%) 0 2
Noninfectious uveitis 6 (2.4%) 3 3
Uveitis 1 (0.4%) 0 1
Behcet’s uveitis 1 (0.4%) 0 1
Iritis 1 (0.4%) 1 0
Vitritis 2 (0.8%) 1 1
Choroiditis 1 (0.4%) 1 0
Endogenous endophthalmitis (bacterial) 5 (1.9%) 1 4
Neuro-ophthalmic 19 (7.6%) 5 14
Cranial nerves/extraocular muscles 7 (2.8%) 0 7
Cranial nerve palsy 7 (2.8%) 0 7
Noninfectious 6 (2.4%) 0 6
Infectious 1 (0.4%) 0 1
Optic nerve 5 (1.9%) 3 2
Optic neuritis 5 (1.9%) 3 2
Infectious 4 (1.6%) 2 2
Noninfectious 1 (0.4%) 1 0
Brain 7 (2.8%) 2 5
Migraine with ocular pain 3 (1.2%) 0 3
Hemianopsia 2 (0.8%) 1 1
Encephalitis with photophobia (infectious) 1 (0.4%) 1 0
Gaze preference (non-infectious) 1 (0.4%) 0 1
FIG. 1. Cytomegalovirus retinitis. This
image was originally published in the
Retina Image Bank ASRS. Author, Jeremy
B. Gross, MD. Uploaded October 10, 2012.
Copyright 2013 American Society of Re-
tina Specialists.
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over this period16 (this includes eye diseases such as CMV: sev-
eral epidemiologic studies of the late 1990’s estimate a 50–80%
decrease in the incidence of CMV retinitis alone since the intro-
duction of ART17–19). Consequently, the incidence of non-AIDS-
related mortality significantly increased over this time period.2–7
Today’s HIV practitioners often face their most significant chal-
lenges fromnoninfectious co-morbidities such as coronary artery
disease, osteoporosis, chronic kidney disease, hyperlipidemia,
liver disease, and non-AIDS defining malignancies.
In our study, noninfectious eye disease was more common
overall than infectious disease. In the early ART group,
however, infections represented the majority of eye diseases
that were seen. The significant decrease in opportunistic in-
fections in the late ART group supports the conclusion that
ART may have been a less effective intervention in the early
ART group. The median time since HIV diagnosis in the early
and late groups was 6 and 7.5 years, respectively. Despite an
average year and a half added exposure to HIV infection, late
ART patients were far less likely to have had an opportunistic
infection. One could subsequently conclude that improved
efficacy of ART in the late group directly impacted the inci-
dence of infectious eye diseases.
A bias towards an increased number of opportunistic in-
fections in the early ART group may very well exist in this
study, however. Many patients in the early ART group may
have acquired their opportunistic infections prior to the
FIG. 3. Progressive outer retinal ne-
crosis. This image was originally pub-
lished in the Retina Image Bank ASRS.
Author, Mallika Goyal, MD. Uploaded
October 31, 2012. Copyright 2013
American Society of Retinal Specialists.
FIG. 2. HIV retinopathy. This
image was originally published
in the Retina Image Bank
ASRS. Author, Alex P. Hunyor,
MD. Uploaded January 11,
2013. Copyright 2013 Amer-
ican Society of Retina Specia-
lists.
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availability of any effective antiretrovirals. They may have
subsequently survived long enough to be included in the
early ART group. Many such patients may not have survived
long enough, however, to be included in the late ART group.
A better understanding of HIV treatment and prevention of
opportunistic infections may have prevented acquisition of
such infections for late ART patients and may partially ac-
count for the decreased prevalence of opportunistic infections
in the late ART group.
An additional caveat exists in that HIV eye diseases that
were frequently managed in the inpatient setting in the 1990s
can now be managed in the outpatient setting. For example, a
regimen of oral valganciclovir in combinationwithART could
now potentially be used to treat CMV retinitis in the outpa-
tient setting. However, such a diagnosis would almost uni-
versally prompt an inpatient admission in the time frame
captured by the early ART group. As this study only exam-
ined eye diseases in inpatients, fewer patients with true in-
fectious eye disease may have been captured in the late ART
group, since these patients may have been able to avoid
hospital admission altogether.
In addition, lack of initial insurance reimbursement for PIs
made their availability to patients impractical in many cases
until the late 1990s. Therefore, despite the existence of PIs
throughout the early ART time period, these effective HIV
medications may not have been widely employed over that
same time frame, and opportunistic infections may therefore
have developed with greater frequency in this group.
The majority of patients with ocular disease, whether in-
fectious or not, experienced diminished visual acuity (when
documented). Patients in the late ART group were signifi-
cantly more likely to have documented visual acuity (< 20/
200) as compared to early ART patients. Our data concur with
other larger studies10 that also illustrate that visual impair-
ment remains a significant problem in the HIV population,
despite improved control of HIV. Emerging noninfectious eye
diseases in HIV patients are likely to continue to have an
impact on vision, despite improved control of HIV. HIV
practitioners, who may be unaware of the potential effects of
FIG. 4. Acute retinal detachment. This image was origin-
ally published in the Retina Image Bank ASRS. Author, Jef-
frey G. Gross, MD. Uploaded October 12, 2012. Copyright
2012 American Society of Retina Specialists.
FIG. 5. Syphilitic maculo-
pathy. This image was origin-
ally published in the Retina
Image Bank ASRS. Author,
Matthew W. MacCumber, MD,
PhD; co-author, Milad Ha-
kimbashi, MD. Photographer,
Tara Farmer. Uploaded Au-
gust 31, 2012. Copyright 2013
American Society of Retina
Specialists.
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noninfectious causes of visual impairment, may inadvertently
leave evolving eye disease unaddressed.
In conclusion, ART has significantly changed the epi-
demiologic landscape of HIV disease. The incidence of life-
threatening opportunistic infections has significantly decreased
in the setting of newer, more efficacious, and better-tolerated
antiretroviral drugs for those individuals who are diagnosed,
who are retained in care, and who remain on ART with a
suppressed viral load. Noninfectious co-morbidities are often
of more pressing concern to the health of HIV patients taking
modern ART regimens.
This generalization appears to be true with regard to eye
disease in the HIV patient as well. Vision-threatening op-
portunistic infections such as CMV retinitis were commonly
seen prior to the development of antiretroviral medications.
Such infections still represented a significant disease burden
amongst patients taking early-generation ART regimens;
however, it appears that newer iterations of ART are causing a
decrease in the incidence of such opportunistic eye infections.
Noninfectious eye diseases now appear to be a more signifi-
cant threat to vision in the late ART HIV patient.
These study data have several limitations. Most notably, this
study is a small, cross-sectional examination with an inherent
selection bias, since only hospitalized patients were included.
These data may not reflect a true representation of eye disease in
the general HIV population. Furthermore, patients without sub-
jective eye complaints may have never received an ocular diag-
nosis, and therefore subclinical eye disease may not have been
discovered. Also of note, some demographic information for the
patients in this study was unavailable and therefore incomplete.
With these limitations in mind, we conclude that our data
provide evidence of a shift in the epidemiology of HIV eye
disease. Noninfectious pathology seems to be a more signifi-
cant cause of visual loss in the late ART era. This observation
is consistent with the shifting epidemiology of HIVmorbidity
and mortality in general and underscores the continued need
for routine eye care as a component of the comprehensive
management of HIV infected patients.
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